Quest Diagnostics (DGX) Q3 2026 earnings review
Quest Diagnostics raises its outlook while test prices fall
Quest Diagnostics handled more medical tests than ever this summer, even though lower-priced hospital contracts pulled down the average fee per order. Revenue rose 10% to $3.10 billion, and operating margin excluding one-offs widened as lower administrative overhead covered lab costs. Chairman and chief executive Jim Davis raised the full-year outlook for a third time, which by our math points to revenue growth slowing to about 9% in the fourth quarter.
| Test order volume from businesses owned a year ago | +14.4% up from +13.0% last quarter |
|---|---|
| Revenue per test order | -4.2% down from -2.8% last quarter |
| Profit per share, excluding one-offs | $3.00 +15.4% from a year ago |
| Full-year revenue outlook | Raised $85M middle of the range: 9.5% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because strong test volumes and automation savings beat what the prior second-half outlook pointed to. Quest also signed a deal to buy outreach lab assets in the Northeast and partnered with Apple to sell blood-test panels inside the Apple Health app. One caution: the drop in average revenue per test order worsened, and unpaid customer bills rose much faster than sales.
The question now is how fast Quest grows once the Corewell Health and Fresenius contracts pass their one-year mark in the fourth quarter. Either specialized tests like the new Alzheimer's panel and consumer orders keep revenue rising near high single digits, or the lap exposes slower base demand. Fourth-quarter volume and pricing excluding those two contracts will settle it.
🐂 Bull Case
Hospital Deals and New Tests Lift the Outlook
Quest Diagnostics runs medical laboratories for doctors, hospitals and consumers. The company has leaned on hospital partnerships—which it calls Co-Lab Solutions—and specialized blood tests to keep order volumes growing without major corporate buyouts. Chief executive Jim Davis said these services meet the needs of an aging population and consumers focused on "prevention and wellness".
Test orders from businesses Quest owned a year ago rose 14.4% this quarter, accelerating from 13.0% in the second quarter. The lab operator signed a deal to "acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S." It also expanded its AD-Detect blood test menu with a new Roche biomarker "to help guide diagnosis and treatment decisions for Alzheimer's disease".
Because test volumes stayed strong through the summer, Quest raised its full-year revenue forecast by $85 million at the middle of the range, to $12.085 billion. By our math, the new full-year plan points to fourth-quarter revenue growth of 8.7%. That marks a mild slowdown as the Corewell Health and Fresenius Medical Care contracts pass their one-year anniversary, rather than a drop in underlying demand.
What to watch: fourth-quarter test order growth excluding the Corewell Health and Fresenius contracts when Quest reports early next year. A reading near 4% or better would confirm that new hospital deals and specialized tests can sustain growth after the big contracts lap.
Automation and Lower Overhead Expanded Operating Margin
Lower-margin hospital contracts and spending on Project Nova, Quest's multi-year upgrade of its ordering and billing software, threatened to squeeze second-half profitability. Instead, Davis credited "productivity gains from automation and AI" for lifting third-quarter earnings.
- Operating margin excluding one-offs: 16.7%, up 0.4 percentage points from a year ago
- Reported operating margin: 15.5%, up 1.8 percentage points (helped by $20 million of prior-year legal and impairment charges not repeating)
- Selling and administrative overhead: 16.9% of revenue, down 0.9 percentage points from a year ago
- Cost of services (running the labs): 66.4% of revenue, up 0.1 percentage points
Overhead savings more than paid for the lab cost pressure, so operating profit excluding one-offs rose 13.0% to $517 million. One quarter eases the second-half margin concern, though Project Nova spending still weighs on the fourth quarter. What to watch: full-year operating margin excluding one-offs in the fourth-quarter report, where a result above last year's 15.9% would prove Quest absorbed the software upgrade.
Apple Health Partnership Opens Direct Consumer Sales
Quest has built a growing business selling lab tests directly to consumers through its website and wellness partners. This quarter the company announced that iPhone and iPad users in the United States will be able to "conveniently purchase a tailored Quest laboratory test panel with over 50 biomarkers directly through the Apple Health app" later this year.
Putting a test menu inside Apple's built-in health app gives Quest reach to millions of device owners without paying for separate consumer advertising. Direct consumer orders also carry higher prices per order because buyers pay out of pocket for broad panels. What to watch: management's disclosure of consumer-channel revenue at the March 25, 2027 Investor Day, which will show whether app partnerships move total company sales.
🐻 Bear Case
Routine Hospital Work Pushes Revenue Per Test Down
Davis highlighted demand for specialized clinical care and wellness panels, which carry multiple tests per order and lift average prices. Yet reported revenue per requisition—the average money Quest collects on each test order—fell 4.2% from a year ago. That drop is steeper than the 2.8% decline in the second quarter and the 1.3% dip in the first quarter.
Routine lab work for Corewell Health and Fresenius dialysis clinics brings in high volume at lower prices per order, pulling the company average down. In prior quarters, management stated on the earnings call that revenue per order excluding those two contracts rose nearly 3%. The press release does not include that adjusted price figure or the dollar sales of specialized tests.
Because the headline price drop widened by 1.4 percentage points from last quarter while organic order growth accelerated by the same 1.4 points, outside readers cannot verify from the release alone that underlying test pricing held steady. What to watch: the revenue-per-order figure excluding Corewell and Fresenius on the conference call, where a drop below 2% would mean the shift toward multi-test panels is slowing.
Unpaid Bills Grow Faster Than Revenue
As Quest expands its hospital outreach and client-billed work, customers are taking longer to pay their bills. Accounts receivable—money owed to Quest for tests already performed—reached $1.71 billion at the end of September. By our math, unpaid bills rose 21.6% from the end of 2025 and 17.6% from a year ago, outpacing the 10.0% rise in third-quarter revenue.
That buildup tied up $308 million of cash over the first nine months of 2026, double the $153 million working-capital drain in the same period last year. As a result, nine-month operating cash flow grew 4.6% while reported net income rose 18.4%. What to watch: days sales outstanding in the third-quarter 10-Q filing, where a rise above 50 days would confirm slower cash collection.
Risks this quarter didn't answer
Three standing policy and legal concerns received no update in the earnings release, and the legal boilerplate flagged one new filing.
- Medicare lab rates (PAMA): 2027 government reimbursement rules remain unsettled; Congressional action or Medicare rate tables in late 2026 will decide whether Quest faces a rate cut.
- Health-exchange subsidies (ACA): management previously baked a 0.3 percentage point revenue drag into 2026 for expiring insurance subsidies; the release gives no update ahead of open enrollment.
- State Medicaid billing probes: New York and Texas inquiries into test-panel billing were not mentioned; the 10-Q legal footnote will show any change in reserves.
- New Form 8-K incident: the forward-looking disclaimer cites "the impact of the incident described in the Current Report on Form 8-K filed on October 22, 2026" without explaining what happened; the 8-K filing itself will provide the details.
👓 Other Themes
Project Nova Moves to the Build Phase
Quest is overhauling its order-to-cash computer systems with healthcare software maker Epic under a multi-year programme called Project Nova. This quarter the company moved Project Nova "from the design phase to the solutions-build phase". Management still plans to install the new Epic software in its first laboratory in the fall of 2027, keeping the project's timeline unchanged.
💲 Other KPIs
Free cash flow—operating cash flow of $611 million minus $166 million of capital spending—grew 6.2% from a year ago by our math, equal to 14.4% of revenue. Operating cash flow rose 8.8%, up from a 9.7% pace in the second quarter, while capital spending for new lab equipment and the Michigan joint-venture build increased 15.0%.
Total debt of $5.55 billion minus $797 million of cash stood at $4.75 billion at quarter-end, down 9.4% from $5.24 billion a year ago by our math. Quest paid off $504 million of maturing debt and borrowed $494 million during the first nine months while building its cash balance by $377 million since December.
By our math, the diagnostic group spent $150 million buying back its own stock in the third quarter ($252 million over nine months minus $102 million in the first half). That lowered the diluted share count by 0.9% from a year ago to 112 million shares, giving a small lift to per-share earnings.
🔮 Guidance
Raised. The middle of the range moved up $85 million to $12.085 billion, or 9.5% growth for the year. By our math, that leaves $3.05 billion for the fourth quarter, or 8.7% growth—down from 10.0% in the third quarter as the Corewell and Fresenius contracts lap. It is the third raise this year: +$80M, +$160M, +$85M.
Raised. Management lifted the middle of the target by $0.15 to $11.30 per share, representing 14.7% full-year growth by our math. That implies $2.68 per share in the fourth quarter, or 10.7% growth from a year ago against 15.4% in the third quarter. It is the third raise of 2026: +$0.13, +$0.42, +$0.15.
Raised. The middle of the range rose $0.19 to $10.26 per share, or 17.3% growth for the year by our math. The new target implies $2.40 per share in the fourth quarter, up 10.1% from a year ago. The full-year reconciliation includes $0.99 per share of acquisition amortization and $0.13 of restructuring costs.
Raised. The lab group added $100 million to its full-year operating cash flow plan, bringing it to $1.90 billion, or 0.7% above 2025 by our math. With $1.486 billion collected in the first nine months, the target implies $414 million in the fourth quarter, down 11.0% from a year ago due to an extra payroll cycle.
Unchanged. The capital spending plan stays at $550 million for the fourth straight quarter, up 4.4% from 2025 by our math. After $418 million spent in the first nine months, the plan leaves $132 million for the fourth quarter, down 16.5% from a year ago.
❓ Key Questions
What was revenue per order excluding Corewell and Fresenius?
Reported revenue per test order fell 4.2%, its steepest drop this year. In prior quarters management disclosed on the call that price and test mix excluding the two big hospital and dialysis contracts rose nearly 3%. Investors need that number to verify underlying pricing.
What is the incident in the October 22 Form 8-K?
The forward-looking disclaimer adds a new risk factor for "the impact of the incident described in the Current Report on Form 8-K filed on October 22, 2026". The release gives no description of the event or whether it carries financial or operational costs.
Why did unpaid customer bills rise 22% since December?
Accounts receivable climbed $308 million over the first nine months to $1.71 billion, growing twice as fast as revenue. Management has previously pointed to client-billed and consumer work, but has not split how much comes from slower payer collection versus mix.
How big is the Alzheimer's and specialized testing business?
Quest launched a new Roche blood test for Alzheimer's disease and credits specialized diagnostics for lifting the number of tests per order. Yet the company has never disclosed the dollar revenue of its specialized testing or brain-health menu.